MapLight Therapeutics, Inc. MPLT Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Business | ||||||
| All Other Segments | $5.31M+3.3% | $5.14M-18.0% | $6.27M+12.4% | $5.58M— | —— | |
| Clinical Trial | $76.34M+42.8% | $53.46M+54.0% | $34.72M+30.0% | $26.71M— | —— | |
| Employee Related | $60.01M+17.5% | $51.06M+88.6% | $27.08M+5.5% | $25.66M— | —— | |
| General And Administrative Expense by Business | ||||||
| Employee Related | $26.62M+22.7% | $21.69M+180% | $7.74M-2.0% | $7.9M— | —— | |
| Professional Fees | $11.18M+23.6% | $9.05M+43.5% | $6.3M+8.2% | $5.82M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does MapLight Therapeutics, Inc. break its business down?
- MapLight Therapeutics, Inc. (MPLT) reports research and development expense by business across 5 parts — All Other Segments, Chemistry Manufacturing And Controls Expenses, Clinical Trial, Employee Related and Preclinical Program. Each is extracted from the segment footnotes and tracked over time.
- Where does MapLight Therapeutics, Inc. 's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in MapLight Therapeutics, Inc. 's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.